Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15028559 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL16504331 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL14990398 | 0.82 | MAPK14 (0.32) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL15007641 | 0.79 | MAPK14 (0.37) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL15007640 | 0.79 | MAPK14 (0.37) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL15007883 | 0.77 | MAPK14 (0.41) | MAPK14MAPK12MAPK11MAPK13 | |
| SCHEMBL15006725 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4MAPK14MAPK12 | |
| SCHEMBL15028544 | 0.76 | MAPK14 (0.38) | MAPK14 | |
| SCHEMBL981551 | 0.76 | PIM1 (0.36) | MAPK14MAPK11 | |
| SCHEMBL15008720 | 0.76 | MAPK14 (0.44) | MAPK14MAPK12MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057273-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK4 | SLC6A2 4577/4885SLC6A3 4458/4885SLC6A4 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.